Pharmaceutical industry payments and assisted reproduction in Australia : a retrospective observational study
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVES: To investigate the extent and nature of pharmaceutical industry payments related to fertility and assisted reproduction in Australia.
DESIGN AND SETTING: This retrospective observational study employed four databases compiled from publicly available pharmaceutical industry transparency reports on educational event sponsorship (October 2011-April 2018), payments to healthcare professionals (October 2015-April 2018) and patient group support (January 2013-December 2017). Analyses were restricted to fertility-related payments by two major manufacturers of fertility medicines in Australia: Merck Serono and Merck, Sharp and Dohme (MSD).
PRIMARY AND SECONDARY OUTCOME MEASURES: Descriptive statistics on fertility-related payments and other transfers of value (counts, total and median costs in Australian dollars) for educational events and to healthcare professionals and patient groups.
RESULTS: Between October 2011 and April 2018, Merck Serono and MSD spent $A4 522 263 on 970 fertility-related events for healthcare professionals, including doctors, nurses and fertility scientists. 56.8% (551/970) events were held by fertility clinics and 29.3% (284/970) by professional medical associations. Between October 2015 and April 2018, Merck Serono spent $A403 800 across 177 payments to 118 fertility healthcare professionals, predominantly for educational event attendance. Recipients included obstetricians and gynaecologists (76.3% of payments, 135/177), nurses (11.3%, 20/177) and embryologists/fertility scientists (9.6%, 17/117). The highest paid healthcare professionals held leadership positions in major fertility clinics. Merck Serono provided $A662 850 to fertility-related patient groups for advocacy and education (January 2013-December 2017).
CONCLUSIONS: The pharmaceutical industry sponsored a broad range of fertility clinicians and organisations, including doctors, nurses, embryologists, professional medical organisations, fertility clinics and patient groups. This sponsorship may contribute to the overuse of fertility services.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
---|---|
Enthalten in: |
BMJ open - 11(2021), 9 vom: 31. Aug., Seite e049710 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Karanges, Emily Aspasia [VerfasserIn] |
---|
Links: |
---|
Themen: |
Journal Article |
---|
Anmerkungen: |
Date Completed 15.09.2021 Date Revised 23.09.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1136/bmjopen-2021-049710 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM330082663 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM330082663 | ||
003 | DE-627 | ||
005 | 20231226203517.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1136/bmjopen-2021-049710 |2 doi | |
028 | 5 | 2 | |a pubmed24n1100.xml |
035 | |a (DE-627)NLM330082663 | ||
035 | |a (NLM)34465582 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Karanges, Emily Aspasia |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pharmaceutical industry payments and assisted reproduction in Australia |b a retrospective observational study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 15.09.2021 | ||
500 | |a Date Revised 23.09.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
520 | |a OBJECTIVES: To investigate the extent and nature of pharmaceutical industry payments related to fertility and assisted reproduction in Australia | ||
520 | |a DESIGN AND SETTING: This retrospective observational study employed four databases compiled from publicly available pharmaceutical industry transparency reports on educational event sponsorship (October 2011-April 2018), payments to healthcare professionals (October 2015-April 2018) and patient group support (January 2013-December 2017). Analyses were restricted to fertility-related payments by two major manufacturers of fertility medicines in Australia: Merck Serono and Merck, Sharp and Dohme (MSD) | ||
520 | |a PRIMARY AND SECONDARY OUTCOME MEASURES: Descriptive statistics on fertility-related payments and other transfers of value (counts, total and median costs in Australian dollars) for educational events and to healthcare professionals and patient groups | ||
520 | |a RESULTS: Between October 2011 and April 2018, Merck Serono and MSD spent $A4 522 263 on 970 fertility-related events for healthcare professionals, including doctors, nurses and fertility scientists. 56.8% (551/970) events were held by fertility clinics and 29.3% (284/970) by professional medical associations. Between October 2015 and April 2018, Merck Serono spent $A403 800 across 177 payments to 118 fertility healthcare professionals, predominantly for educational event attendance. Recipients included obstetricians and gynaecologists (76.3% of payments, 135/177), nurses (11.3%, 20/177) and embryologists/fertility scientists (9.6%, 17/117). The highest paid healthcare professionals held leadership positions in major fertility clinics. Merck Serono provided $A662 850 to fertility-related patient groups for advocacy and education (January 2013-December 2017) | ||
520 | |a CONCLUSIONS: The pharmaceutical industry sponsored a broad range of fertility clinicians and organisations, including doctors, nurses, embryologists, professional medical organisations, fertility clinics and patient groups. This sponsorship may contribute to the overuse of fertility services | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Observational Study | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a medical education & training | |
650 | 4 | |a medical ethics | |
650 | 4 | |a reproductive medicine | |
700 | 1 | |a Nangla, Conrad |e verfasserin |4 aut | |
700 | 1 | |a Parker, Lisa |e verfasserin |4 aut | |
700 | 1 | |a Fabbri, Alice |e verfasserin |4 aut | |
700 | 1 | |a Farquhar, Cynthia |e verfasserin |4 aut | |
700 | 1 | |a Bero, Lisa |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2012 |g 11(2021), 9 vom: 31. Aug., Seite e049710 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2021 |g number:9 |g day:31 |g month:08 |g pages:e049710 |
856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2021-049710 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 11 |j 2021 |e 9 |b 31 |c 08 |h e049710 |